Hostname: page-component-7bb8b95d7b-dtkg6 Total loading time: 0 Render date: 2024-09-25T21:54:26.034Z Has data issue: false hasContentIssue false

Genetic polymorphisms in selenoprotein P gene affect colorectal, prostate and breast cancer risk

Published online by Cambridge University Press:  30 August 2013

Catherine Méplan
Affiliation:
Institute for Cell and Molecular Biosciences, Newcastle University, Newcastle-upon-Tyne, NE2 4HH, UK Human Nutrition Research Centre, Newcastle University, Newcastle-upon-Tyne, NE2 4HH, UK
John Hesketh
Affiliation:
Institute for Cell and Molecular Biosciences, Newcastle University, Newcastle-upon-Tyne, NE2 4HH, UK Human Nutrition Research Centre, Newcastle University, Newcastle-upon-Tyne, NE2 4HH, UK
Rights & Permissions [Opens in a new window]

Abstract

Type
Abstract
Copyright
Copyright © The Authors 2013 

Selenium (Se) is incorporated into various selenoproteins which mediate its biological roles. Selenoproteins play a major role in oxidative and ER stress response and mitochondrial function. Homeostatic dysregulation of these mechanisms is implicated in many age-related disorders including cancer. Suboptimal selenium status, as found in Europe, has been associated with increased cancer incidence. Selenoprotein expression and activity depends on bioavailability of Se. Selenoprotein P (SePP) is the major plasma transporter of Se and it delivers hepatic selenium to tissues to support the synthesis of other selenoproteins. Two single nucleotide polymorphisms (SNP) that affect SePP plasma isoform pattern and expression of other selenoproteins were identified in the SEPP1 gene (rs3877899, rs7579)( Reference Meplan, Crosley and Nicol 1 , Reference Meplan, Nicol and Burtle2 ), suggesting that these SNPs affected Se bioavailability for the synthesis of other selenoproteins. Rs7579 induces a G/A base change in the 3′ untranslated region of SEPP1 mRNA in a region close to a regulatory element required for SePP synthesis and rs3877899 induces an amino acid change at position 234 from Alanine to Threonine. To determine the impact of these SNPS on cancer risk, we compared their effects on colorectal, prostate and breast cancer risk using data from three European case-control cohorts. There was an association between rs7579 genotype in SEPP1 and prostate and colorectal cancer risk in males, with men homozygous for the rare allele (AA) having an increased risk of developing prostate cancer (OR, 1.72; 95% CI, 0.99–2.98) and colorectal cancer (OR, 1.67; 95% CI, 1.07–2.60)( Reference Meplan, Hughes and Pardini 3 , Reference Steinbrecher, Meplan and Hesketh4 ). In addition, in a recent collaboration we found that females homozygous for the rare allele (AA) for rs3877899 showed a dramatically reduced risk of developing breast cancer. A non-significant reduction of prostate cancer risk was also observed in homozygous AA for rs3877899 (OR, 0.66; 95% CI, 0.31–1.39). However in another population, a genetic interaction was found between rs3877899 and a SNP in the SOD2, encoding for the mitochondrial superoxide dismutase, with an increased prostate cancer risk in male smokers homozygous AA who were SOD2-Val16 homozygotes( Reference Cooper, Adami and Gronberg 5 ). Taken together our studies suggest that genotype for these two SEPP1 variants affects cancer risk.

Further studies of larger cohorts and incorporating both genotype and Se status are needed to confirm these effects. Since selenoproteins are essential to many stress responses, and their expression is regulated by dietary Se intake, they represent prime targets for modulating an individual's susceptibility to stressors by changes in diet. Factors, such as SEPP1 genetic polymorphisms, which influence Se bioavailability, could impact on the capacity of an individual to respond to stressors thus affecting cancer risk.

References

1. Meplan, C, Crosley, LK, Nicol, F et al. (2007) Faseb J 21, 30633074.Google Scholar
2. Meplan, C, Nicol, F, Burtle, BT et al. (2009) Antioxid Redox Signal 11, 26312640.Google Scholar
3. Meplan, C, Hughes, DJ, Pardini, B et al. (2010) Carcinogenesis 31, 10741079.Google Scholar
4. Steinbrecher, A, Meplan, C, Hesketh, J et al. (2010) Cancer Epidemiol Biomarkers Prev 19, 29582968.Google Scholar
5. Cooper, ML, Adami, HO, Gronberg, H et al. (2010) Cancer Res 68, 1017110177.Google Scholar